[Clinical manifestations, course and outcome of enzyme replacement therapy in Hungarian patients with Pompe's disease]

Orv Hetil. 2011 Sep 25;152(39):1569-75. doi: 10.1556/OH.2011.29184.
[Article in Hungarian]

Abstract

Pompe's disease is an autosomal recessive disease caused by deficiency of acid-alpha-glucosidase.

Aims and methods: Authors analyzed the phenotype of 11 Hungarian patients with Pompe's disease and evaluated clinical parameters and response to enzyme replacement therapy during a long-term follow-up in 8 patients.

Results: One patient with atypical infantile form presented with cardiomyopathy and a very slow progression of motor deficits; after 2 years of enzyme replacement therapy no disability was present at the age 6 years. Another patient was asymptomatic at the age of 2.5 years. The adult onset form was characterized by slight to prominent limb-girdle myopathy with an age of onset between 20 and 50 years. In 3 of such cases respiratory insufficiency was also present.

Conclusions: Hungarian patients with Pompe's disease presented with a wide phenotypic variability ranging from atypical early childhood form with slowly progressive course to late-onset limb-girdle myopathy with variable courses. Enzyme replacement therapy resulted in significant improvement in motor and respiratory functions in most of the patients.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Age of Onset
  • Carbon Dioxide / metabolism
  • Child
  • Child, Preschool
  • Disease Progression
  • Enzyme Replacement Therapy* / methods
  • Female
  • Forced Expiratory Volume
  • Glycogen Storage Disease Type II / drug therapy
  • Glycogen Storage Disease Type II / enzymology*
  • Glycogen Storage Disease Type II / genetics*
  • Glycogen Storage Disease Type II / physiopathology
  • Humans
  • Hungary
  • Male
  • Middle Aged
  • Oxygen / metabolism
  • Phenotype
  • Respiratory Insufficiency / enzymology
  • Respiratory Insufficiency / etiology*
  • Respiratory Insufficiency / physiopathology
  • Time Factors
  • alpha-Glucosidases / deficiency*
  • alpha-Glucosidases / genetics
  • alpha-Glucosidases / therapeutic use*

Substances

  • Carbon Dioxide
  • alpha-Glucosidases
  • Oxygen